Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.
about
Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor AgonistsA clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyondThe Impact of Glucagon-Like Peptide-1 on Bone Metabolism and Its Possible Mechanisms.An indirect comparison of HbA1c treatment effect with albiglutide and exenatide 2.0 mg QW using the Bucher methodReal-world comparison of treatment patterns and effectiveness of albiglutide and liraglutide.Albiglutide: a unique GLP-1 receptor agonist.Cardiovascular safety and benefits of GLP-1 receptor agonists.Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide.The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy.The safety of albiglutide for the treatment of type 2 diabetes.Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes.Semaglutide-the "new kid on the block" in the field of glucagon-like peptide-1 receptor agonists?Comparative effectiveness of once-weekly glucagon-like peptide-1 receptor agonists with regard to 6-month glycaemic control and weight outcomes in patients with type 2 diabetes.Albiglutide efficacy and safety in the Latino/Hispanic subpopulation for the integrated phase III program.Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trials.Editorial: Bone: Endocrine Target and Organ.Exendin-4 promotes the osteogenic differentiation of osteoblasts via the Hedgehog/Gli1 signaling pathway.Weekly glucagon-like peptide-1 receptor agonist albiglutide as monotherapy improves glycemic parameters in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study.Effect of Albiglutide on Cholecystokinin-Induced Gallbladder Emptying in Healthy Individuals: A Randomized Crossover Study.Albiglutide, a weekly GLP-1 receptor agonist, improves glycemic parameters in Japanese patients with type 2 diabetes over 1 year when added to single oral antidiabetic drugs.Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials.Gastrointestinal safety across the albiglutide development programme.
P2860
Q26749495-C89ED83B-C5EC-422D-99D2-A3AAFB0947C2Q26799389-6BC52699-D7C7-4C96-BF05-36007CE45792Q33627749-FA100765-59D3-4534-A598-2A297A9C2182Q36926587-73D83390-7E8F-44EE-A164-4EEF5EEBC641Q38621798-0F725FA9-B92A-47B7-B4A9-23C611D5B36AQ38966029-CD246DF6-A4F3-42E1-BA28-05D81749C8D3Q39013056-B1E39AD1-7038-4A2F-BE5B-7EB412E7E80AQ39041615-79EFFBDA-5FAB-4392-841D-1A4954D66BB7Q39140294-8C80A7F5-7823-4989-999D-FA7EE014B93EQ39415439-0C7D63F8-8903-4083-96C0-978239D522DFQ41184651-6F5E8DD9-AD9B-4329-B724-2E91BBC34AB7Q47097015-F7E49522-3DAA-48BC-8F7B-32969F8EA16EQ47190800-13E28FF4-96D5-452D-B748-B1FE61F6E0F1Q47588862-34E271F5-D734-4828-933B-4D8AD5391CC2Q48317531-CAFCC3ED-67AC-4768-9E59-024D31310894Q49192890-203F7F04-F63E-4631-8950-46FD2803D586Q49371368-4E46FC6B-8AED-45D1-ACBF-4441FB2190DCQ50044622-EE0C091A-B224-48AF-A44E-5237C0D6B032Q50623738-551EA5D5-2E5A-4E7F-95E3-2A22E4B78A10Q51276253-9159A64B-E36A-47DE-9957-9F3BA4EEBA68Q51320034-B8E02CDC-2129-49A0-8A21-B28ACBC0BD7AQ53162146-F515E1FF-CB22-463C-A237-FA4D60A4DF75
P2860
Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Efficacy and safety of once-we ...... rolled with diet and exercise.
@ast
Efficacy and safety of once-we ...... rolled with diet and exercise.
@en
type
label
Efficacy and safety of once-we ...... rolled with diet and exercise.
@ast
Efficacy and safety of once-we ...... rolled with diet and exercise.
@en
prefLabel
Efficacy and safety of once-we ...... rolled with diet and exercise.
@ast
Efficacy and safety of once-we ...... rolled with diet and exercise.
@en
P2093
P2860
P1433
P1476
Efficacy and safety of once-we ...... rolled with diet and exercise.
@en
P2093
Angela Jones-Leone
Caroline Perry
Christopher Perkins
Marc Rendell
Michael A Nauck
Murray W Stewart
Rickey R Reinhardt
P2860
P2888
P304
P356
10.1007/S00125-015-3795-1
P577
2015-11-17T00:00:00Z